Skip Navigation LinksHome > February 01, 2014 - Volume 39 - Issue 3 > Multicenter Prospective Nonrandomized Controlled Clinical Tr...
Spine:
doi: 10.1097/BRS.0000000000000121
Cervical Spine

Multicenter Prospective Nonrandomized Controlled Clinical Trial to Prove Neurotherapeutic Effects of Granulocyte Colony-Stimulating Factor for Acute Spinal Cord Injury: Analyses of Follow-up Cases After at Least 1 Year

Inada, Taigo MD*; Takahashi, Hiroshi MD, PhD*; Yamazaki, Masashi MD, PhD*; Okawa, Akihiko MD, PhD*; Sakuma, Tsuyoshi MD, PhD*; Kato, Kei MD*; Hashimoto, Mitsuhiro MD*; Hayashi, Koichi MD, PhD*; Furuya, Takeo MD, PhD*; Fujiyoshi, Takayuki MD, PhD*; Kawabe, Junko MD, PhD*; Mannoji, Chikato MD, PhD*; Miyashita, Tomohiro MD, PhD*; Kadota, Ryo MD, PhD*; Someya, Yukio MD, PhD*; Ikeda, Osamu MD, PhD*; Hashimoto, Masayuki MD, PhD*; Suda, Kota MD, PhD; Kajino, Tomomichi MD, PhD; Ueda, Haruki MD; Ito, Yasuo MD, PhD; Ueta, Takayoshi MD, PhD§; Hanaoka, Hideki MD, PhD; Takahashi, Kazuhisa MD, PhD*; Koda, Masao MD, PhD*

Collapse Box

Abstract

Study Design. An open-labeled multicenter prospective nonrandomized controlled clinical trial.

Objective. To confirm the feasibility of using granulocyte colony-stimulating factor (G-CSF) for treatment of acute spinal cord injury (SCI).

Summary of Background Data. We previously reported that G-CSF promotes functional recovery after compression-induced SCI in mice. On the basis of these findings, we conducted a multicenter prospective controlled clinical trial to assess the feasibility of G-CSF therapy for patients with acute SCI.

Methods. The trial ran from August 2009 to March 2011, and included 41 patients with SCI treated within 48 hours of onset. Informed consent was obtained from all patients. After providing consent, patients were divided into 2 groups. In the G-CSF group (17 patients), G-CSF (10 μg/kg/d) was intravenously administered for 5 consecutive days, and in the control group (24 patients), patients were similarly treated except for the G-CSF administration. We evaluated motor and sensory functions using the American Spinal Cord Injury Association score and American Spinal Cord Injury Association impairment scale at 1 week, 3 months, 6 months, and 1 year after onset.

Results. Only 2 patients did not experience American Spinal Cord Injury Association impairment scale improvement in the G-CSF group. In contrast, 15 patients in the control group did not experience American Spinal Cord Injury Association impairment scale improvement. In the analysis of increased American Spinal Cord Injury Association motor score, a significant increase in G-CSF group was detected from 1 week after the administration compared with the control group. After that, some spontaneous increase of motor score was detected in control group, but the significant increase in G-CSF group was maintained until 1 year of follow-up.

Conclusion. Despite the limitation that patient selection was not randomized, the present results suggest the possibility that G-CSF administration has beneficial effects on neurological recovery in patients with acute SCI.

Level of Evidence: 3

© 2014 by Lippincott Williams & Wilkins

Follow Us!

  

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.